Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort o... by Aaron R. Hansen, Stephan Probst, Jean-Mathieu Beauregard, Benjamin L. Viglianti, Jeff M. Michalski, Scott T. Tagawa, Oliver Sartor, Ronald F. Tutrone, Orhan K. Oz, Kevin D. Courtney, Ebrahim S. Delpassand, Luke T. Nordquist, Medhat M. Osman, Kim N. Chi, Richard Sparks, Noble George, Sara M. Hawley, Wenting Wu, Jessica D. Jensen, Neil E. Fleshner

“…Here we report those results.MethodsEnrolled participants had mCRPC that progressed on one prior androgen receptor pathway inhibitor (ARPI), were prostate-specific membrane antigen (PSMA) PET–positive as determined by a central reader, were chemotherapy-naïve for mCRPC, and had adequate bone marrow and end-organ reserve. Participants received up to 4 cycles of [177Lu]Lu-PNT2002 at 6.8 GBq (± 10%) intravenously per cycle every 8 weeks. …”
Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

Get full text

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS by Thomas Cluzeau, Fabio Guolo, Edmond Chiche, Paola Minetto, Ramy Rahme, Sarah Bertoli, Luana Fianchi, Jean-Baptiste Micol, Michele Gottardi, Pierre Peterlin, Sara Galimberti, Xavier Thomas, Giuliana Rizzuto, Olivier Legrand, Michela Rondoni, Emmanuel Raffoux, Giambattista Bertani, Alexis Caulier, Michelina D’Argenio, Caroline Bonmati, Atto Billio, Caroline Lejeune, Barbara Scappini, Arnaud Pigneux, Patrizia Zappasodi, Christan Recher, Francesco Grimaldi, Lionel Ades, Roberto M. Lemoli

Get full text

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM by Krzysztof Kalwak, Laura M. Moser, Ulrike Pötschger, Peter Bader, Katharina Kleinschmidt, Roland Meisel, Jean-Hugues Dalle, Akif Yesilipek, Adriana Balduzzi, Gergely Krivan, Evgenios Goussetis, Raquel Staciuk, Petr Sedlacek, Herbert Pichler, Peter Svec, Melissa Gabriel, Tayfun Güngör, Ernest Bilic, Jochen Buechner, Marleen Renard, Kim Vettenranta, Marianne Ifversen, Cristina Diaz-de-Heredia, Jerry Stein, Jacek Toporski, Marc Bierings, Christina Peters, Marc Ansari, Franco Locatelli

Get full text

High paracrine activity of hADSCs cartilage microtissues inhibits extracellular matrix degradation and promotes cartilage regeneration by Wei Liu, Hongyu Jiang, Jiajie Chen, Yue Tian, Ying He, Ying Jiao, Yanjun Guan, Zhibo Jia, Yanbin Wu, Cheng Huang, Yiben Ouyang, Wenjing Xu, Jianhong Qi, Jiang Peng, Aiyuan Wang

“…Autologous adipose-derived mesenchymal stem cells (ADSCs) and bone marrow mesenchymal stem cells (BMSCs) are widely used in cartilage tissue engineering. …”
Get full text

Protocol for engineering bone organoids from mesenchymal stem cells by Jian Wang, Dongyang Zhou, Ruiyang Li, Shihao Sheng, Guangfeng Li, Yue Sun, Peng Wang, Yulin Mo, Han Liu, Xiao Chen, Zhen Geng, Qin Zhang, Yingying Jing, Long Bai, Ke Xu, Jiacan Su

“…To address this issue, we propose a three-dimensional (3D) construction strategy for generating mineralized bone structures using bone marrow-derived mesenchymal stem cells (BMSCs). …”
Get full text

Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts by Kelley Weinfurtner, David Tischfield, George McClung, Jennifer Crainic, John Gordan, Jing Jiao, Emma E. Furth, Wuyan Li, Erena Tuzneen Supan, Gregory J. Nadolski, Stephen J. Hunt, David E. Kaplan, Terence P.F. Gade

“…Finally, utilizing adult bone marrow instead of fetal livers enabled partial HLA-matching to HCC tumors but required more CD34+ cells. …”
Get full text

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab by Meng Wu, Claudia A.M. Fulgenzi, Antonio D’Alessio, Alessio Cortellini, Ciro Celsa, Giulia F. Manfredi, Bernardo Stefanini, Y. Linda Wu, Yi-Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei-Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang

Get full text